252 related articles for article (PubMed ID: 28928213)
21. Discovery of 2-(1H-imidazo-2-yl)piperazines as a new class of potent and non-cytotoxic inhibitors of Trypanosoma brucei growth in vitro.
Ferrigno F; Biancofiore I; Malancona S; Ponzi S; Paonessa G; Graziani R; Bresciani A; Gennari N; Di Marco A; Kaiser M; Summa V; Harper S; Ontoria JM
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3689-3692. PubMed ID: 30482621
[TBL] [Abstract][Full Text] [Related]
22. Drug resistance in Trypanosoma brucei spp., the causative agents of sleeping sickness in man and nagana in cattle.
Matovu E; Seebeck T; Enyaru JC; Kaminsky R
Microbes Infect; 2001 Jul; 3(9):763-70. PubMed ID: 11489425
[TBL] [Abstract][Full Text] [Related]
23. The trypanosome alternative oxidase: a potential drug target?
Menzies SK; Tulloch LB; Florence GJ; Smith TK
Parasitology; 2018 Feb; 145(2):175-183. PubMed ID: 27894362
[TBL] [Abstract][Full Text] [Related]
24. How do the alkaloids emetine and homoharringtonine kill trypanosomes? An insight into their molecular modes of action.
Krstin S; Mohamed T; Wang X; Wink M
Phytomedicine; 2016 Dec; 23(14):1771-1777. PubMed ID: 27912879
[TBL] [Abstract][Full Text] [Related]
25. Potent antitrypanosomal activities of heat shock protein 90 inhibitors in vitro and in vivo.
Meyer KJ; Shapiro TA
J Infect Dis; 2013 Aug; 208(3):489-99. PubMed ID: 23630365
[TBL] [Abstract][Full Text] [Related]
26. Combining tubercidin and cordycepin scaffolds results in highly active candidates to treat late-stage sleeping sickness.
Hulpia F; Mabille D; Campagnaro GD; Schumann G; Maes L; Roditi I; Hofer A; de Koning HP; Caljon G; Van Calenbergh S
Nat Commun; 2019 Dec; 10(1):5564. PubMed ID: 31804484
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of isoleucyl-tRNA synthetase as a potential treatment for human African Trypanosomiasis.
Cestari I; Stuart K
J Biol Chem; 2013 May; 288(20):14256-14263. PubMed ID: 23548908
[TBL] [Abstract][Full Text] [Related]
28. Chalcone, acyl hydrazide, and related amides kill cultured Trypanosoma brucei brucei.
Troeberg L; Chen X; Flaherty TM; Morty RE; Cheng M; Hua H; Springer C; McKerrow JH; Kenyon GL; Lonsdale-Eccles JD; Coetzer TH; Cohen FE
Mol Med; 2000 Aug; 6(8):660-9. PubMed ID: 11055585
[TBL] [Abstract][Full Text] [Related]
29. Bioluminescent imaging of Trypanosoma brucei shows preferential testis dissemination which may hamper drug efficacy in sleeping sickness.
Claes F; Vodnala SK; van Reet N; Boucher N; Lunden-Miguel H; Baltz T; Goddeeris BM; Büscher P; Rottenberg ME
PLoS Negl Trop Dis; 2009 Jul; 3(7):e486. PubMed ID: 19621071
[TBL] [Abstract][Full Text] [Related]
30. In vitro anti-trypanosomal effects of selected phenolic acids on Trypanosoma brucei.
Amisigo CM; Antwi CA; Adjimani JP; Gwira TM
PLoS One; 2019; 14(5):e0216078. PubMed ID: 31048849
[TBL] [Abstract][Full Text] [Related]
31. Chemical validation of GPI biosynthesis as a drug target against African sleeping sickness.
Smith TK; Crossman A; Brimacombe JS; Ferguson MA
EMBO J; 2004 Nov; 23(23):4701-8. PubMed ID: 15526036
[TBL] [Abstract][Full Text] [Related]
32. Design and Synthesis of Brain Penetrant Trypanocidal N-Myristoyltransferase Inhibitors.
Bayliss T; Robinson DA; Smith VC; Brand S; McElroy SP; Torrie LS; Mpamhanga C; Norval S; Stojanovski L; Brenk R; Frearson JA; Read KD; Gilbert IH; Wyatt PG
J Med Chem; 2017 Dec; 60(23):9790-9806. PubMed ID: 29125744
[TBL] [Abstract][Full Text] [Related]
33. Ethyl Pyruvate Emerges as a Safe and Fast Acting Agent against Trypanosoma brucei by Targeting Pyruvate Kinase Activity.
Worku N; Stich A; Daugschies A; Wenzel I; Kurz R; Thieme R; Kurz S; Birkenmeier G
PLoS One; 2015; 10(9):e0137353. PubMed ID: 26340747
[TBL] [Abstract][Full Text] [Related]
34. 6-phosphogluconate dehydrogenase: a target for drugs in African trypanosomes.
Hanau S; Rinaldi E; Dallocchio F; Gilbert IH; Dardonville C; Adams MJ; Gover S; Barrett MP
Curr Med Chem; 2004 Oct; 11(19):2639-50. PubMed ID: 15544466
[TBL] [Abstract][Full Text] [Related]
35. Orally Active and Selective Tubulin Inhibitors as Anti-Trypanosome Agents.
Nanavaty V; Lama R; Sandhu R; Zhong B; Kulman D; Bobba V; Zhao A; Li B; Su B
PLoS One; 2016; 11(1):e0146289. PubMed ID: 26771307
[TBL] [Abstract][Full Text] [Related]
36. Trypanosome alternative oxidase as a target of chemotherapy.
Nihei C; Fukai Y; Kita K
Biochim Biophys Acta; 2002 Jul; 1587(2-3):234-9. PubMed ID: 12084465
[TBL] [Abstract][Full Text] [Related]
37. Trypanosome alternative oxidase: from molecule to function.
Chaudhuri M; Ott RD; Hill GC
Trends Parasitol; 2006 Oct; 22(10):484-91. PubMed ID: 16920028
[TBL] [Abstract][Full Text] [Related]
38. Trypanosoma brucei: effects of methoprene and other isoprenoid compounds on procyclic and bloodstream forms in vitro and in mice.
Harmon MA; Scott TC; Li Y; Boehm MF; Phillips MA; Mangelsdorf DJ
Exp Parasitol; 1997 Nov; 87(3):229-36. PubMed ID: 9371088
[TBL] [Abstract][Full Text] [Related]
39. A novel protein kinase is essential in bloodstream Trypanosoma brucei.
Jensen BC; Booster N; Vidadala RS; Maly DJ; Parsons M
Int J Parasitol; 2016 Jul; 46(8):479-83. PubMed ID: 27018127
[TBL] [Abstract][Full Text] [Related]
40. Novel distamycin analogues that block the cell cycle of African trypanosomes with high selectivity and potency.
Franco J; Scarone L; Comini MA
Eur J Med Chem; 2020 Mar; 189():112043. PubMed ID: 31978782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
